Heart Seed <219A>
Revised financial estimates for the fiscal year ending October 2024. Revenue was revised upward from 15.3 billion yen to 0.874 billion yen, and operating loss was revised from a deficit of 1.965 billion yen to a deficit of 105.9 billion yen. Under an exclusive technology partnership and licensing agreement with Novo Nordisk A/S covering worldwide, the development milestone expected for the fiscal year ending October 2025 was achieved earlier in the fiscal year ending October 2024. In addition, expenses for sales, general administration, and research and development, including testing costs and costs for myocardial cell production, were lower than anticipated.
Pal HD <2726>
Yesterday, there was a sudden surge in trading up to 3,070 yen, breaking the previous highest price. The Bollinger Bands have quickly broken above +3σ, indicating a potential overheating situation that needs to be monitored closely. However, on the weekly chart, as the bands trend upwards, they have finally crossed over +2σ. The price has risen to around 3,235 yen at +3σ, suggesting a trend formation following the band's expansion.